Abstract: The technology provided herein generally relates relates to genetically modified higher plants, for example C3 and C4 plants, and subsequent generations thereof, comprising stable and/or transient expression of at least one gene-product (e.g. mRNA or protein) of the “Chlamydomonas reinhardtii CO2 concentrating mechanism” (CCM), wherein the expression takes place in the intermembrane space and/or one or more subcellular compartments of the chloroplasts of the higher plant, and wherein this expression increases one or more of the characteristics selected from the group of photosynthetic rate, photosynthetic carbon fixation, chlorophyll level and/or biomass of the genetically modified higher plant (T0) and/or of the T1 and/or T2 generation or any subsequent plant generation of said genetically modified higher plant.

Abstract: This disclosure concerns nucleic acid molecules and methods of use thereof for control of insect pests through RNA interference-mediated inhibition of target coding and transcribed non-coding sequences in insect pests, including coleopteran and/or hemipteran pests. The disclosure also concerns methods for making transgenic plants that express nucleic acid molecules useful for the control of insect pests, and the plant cells and plants obtained thereby.

Abstract: The technology provided herein relates to novel anti-parasitic complexes, in particular recombinant fusion proteins suitable as human and/or animal drugs against a parasite of the phylum Apicomplexa, in particular against Plasmodium falciparum (P. falciparum) comprising at least one component A and at least one component B, characterized in that component A has a binding activity for cellular surface structures presented on the surface of a parasite of the phylum Apicomplexa or for parasitic antigens presented on a parasitized host cell, and component B is a compound having anti-parasitic activity.

Abstract: The technology provided herein relates to novel malaria vaccines composed of different recombinant proteins, in particular recombinant fusion proteins comprising several different Plasmodium falciparum antigens from the pre-erythrocytic, the blood, and the sexual parasite main stages. The proteins may be used in a mixture vaccine formulation to elicit protective immune responses in humans. Nucleic acid molecules encoding said recombinant proteins, vectors and host cells containing the nucleic acids and methods for preparation and producing such proteins are also disclosed, as well as antibodies induced or generated by the use of said malaria vaccines and the use of such antibodies or recombinant derivatives for passive immunotherapy.

Abstract: This disclosure concerns nucleic acid molecules and methods of use thereof for control of insect pests through RNA interference-mediated inhibition of target coding and transcribed non-coding sequences in insect pests, including coleopteran and/or hemipteran pests. The disclosure also concerns methods for making transgenic plants that express nucleic acid molecules useful for the control of insect pests, and the plant cells and plants obtained thereby.

Abstract: This disclosure concerns nucleic acid molecules and methods of use thereof for control of insect pests through RNA interference-mediated inhibition of target coding and transcribed non-coding sequences in insect pests, including coleopteran and/or hemipteran pests. The disclosure also concerns methods for making transgenic plants that express nucleic acid molecules useful for the control of insect pests, and the plant cells and plants obtained thereby.

Abstract: A composition comprising as components a polypeptide IMPI? (including wild type) and/or a polypeptide IMPI?-fusion and at least one antibiotic compound, in particular an aminoglycoside antibiotic, and/or at least one bactericidal compound, wherein the polypeptides, the at least one antibiotic and the at least one bactericidal compound is present in the composition in concentrations which exhibit in combination a synergistic effect against resistant bacteria.

Abstract: The present disclosure relates to novel malaria vaccines composed of different recombinant proteins, in particular recombinant fusion proteins comprising several different Plasmodium falciparum antigens from the pre-erythrocytic the blood, and the sexual parasite stages. The proteins and/or fusion proteins will be used in a mixture vaccine formulation to elicit protective immune responses in humans. Nucleic acid molecules encoding said recombinant proteins, vectors, host cells containing the nucleic acids and methods for preparation and producing such proteins; Antibodies induced or generated by the use of said malaria vaccines or said nucleic acid molecules encoding said proteins and/or fusion proteins and the use of such antibodies or recombinant derivatives for passive immunotherapy.

Abstract: The technology provided herein relates to novel human antibodies against Plasmodium parasites, in particular against the malaria parasite Plasmodium falciparum. The present disclosure pertains to antibodies against merozoite surface protein 10 (MSP10). These antibodies have high affinity e.g. to Plasmodium falciparum schizonts and merozoites, inhibit the reinvasion of merozoites into erythrocytes and thereby neutralize parasitic multiplication.

Abstract: A supplemental device (2) for attachment to a pen-type drug injection device, the supplemental device comprising an optical sensor array or camera (25) configured to capture an image of one or more numbers representing dose values on a dose dial sleeve of the injection device, and a processor (24) and memory (240,241) arrangement configured to run an algorithm to receive image data from the sensor/camera and extract the dialed dose value from said image via optical character recognition (OCR). The algorithm is able to determine the set dose value which is at the centre of the image (902), also if the dose scale only comprises integer values in steps of two (see FIG. 9).

Abstract: A peptide having an amino acid sequence containing at least eight consecutive amino acids of the human lactoferrin protein or of the bovine lactoferrin protein. The peptide is suitable as a cell-penetrating peptide. A complex of the peptide and a cargo molecule non-covalently bound to the peptide. The cargo molecule may be a nucleic acid, an amino acid, a peptide, a protein, a carbohydrate, a lipid, or a small molecule. A method of penetrating or transfecting a cell using the complex.

Abstract: The technology provided herein relates to novel variants of microbial glucose oxidase with improved properties, more specifically to polypeptides having glucose oxidase activity as their major enzymatic activity; to nucleic acid molecules encoding the glucose oxidases; vectors and host cells containing the nucleic acids and methods for producing the glucose oxidase; compositions comprising the glucose oxidase; methods for the preparation and production of such enzymes; and to methods for using such enzymes for food and feed processing, for the measurement of free glucose in clinical samples and bioreactors, and the development of miniature biofuel cells.

Abstract: A polypeptide having at least 70% homology, in particular 80%, 90% or 95% homology to the polypeptide of SEQ ID NO:2 representing the wild-type of the protein insect metalloproteinase inhibitor IMPI? and having at least one mutation at position 35, 36 and/or 39 of the amino acid sequence of IMPI? and the polypeptide having an IC50 value to thermolysine of less than the IC50 value of IMPI? wherein the nonpolar amino acid isoleucine at position 35 of IMPI? is replaced either by a nonpolar amino acid selected from the group consisting of leucine, methionine and phenylalanine or by polar amino acid selected from the group consisting of cysteine, asparagine, glutamine, histidine, lysine and arginine; and/or the nonpolar amino acid isoleucine at position 36 of IMPI? is replaced either by a nonpolar amino acid selected from the group consisting of valine, phenylalanine and tryptophan or by polar amino acid selected from the group consisting of tyrosine, serine, threonine, asparagine, glutamine, histidine, lysine and

Abstract: A method of penetrating a cell where the cell is contacted with a complex that includes (A) a peptide comprising at least 8 consecutive amino acids of the human lactoferrin protein or of the bovine lactoferrin protein; and (B) a cargo molecule bound to the peptide.

Abstract: The present invention relates to kits comprising plus-sense single stranded RNA viral vectors, as well as mixtures of these vectors and uses thereof, and methods for producing in a plant, or plant tissue, or plant cell simultaneously two or more polypeptides using the kits and vectors.

Abstract: The technology provided herein relates to methods of multi-species insect pest control by incorporating an inhibitor against the structural sheath protein (SHP) into the body of an agricultural target pest, and to pest control agents to be used in the method and to transgenic crop, greenhouse and ornamental plants.

Abstract: Method for producing an isoindole derivative, the isoindole derivative obtainable by the methods, a methods for stabilizing an isoindole derivative, and methods for detection and/or quantification of macromolecules.

Abstract: The technology provided herein generally relates to novel fusion proteins suitable as human and/or animal vaccines against parasites or pathogens of the phylum Apicomplexa. In particular, the present disclosure relates to novel fusion proteins as a basis for vaccines against Plasmodium parasites, including P. falciparum, P. vivax, P. malariae, P. ovale and P. knowlesi. Nucleic acid molecules encoding said fusion proteins, vectors, host cells containing the nucleic acids and methods for preparation and producing such fusion proteins; antibodies induced or generated by the use of said fusion proteins or said nucleic acid molecules encoding said fusion proteins and the use of such antibodies or recombinant derivatives for passive immunotherapy; methods for producing such fusion proteins; compositions and methods for using such fusion proteins for the prevention and treatment of malaria are also encompassed by the present disclosure.

Abstract: The technology provided herein relates to novel variants of microbial glucose oxidase with improved properties, more specifically to polypeptides having glucose oxidase activity as their major enzymatic activity; to nucleic acid molecules encoding said glucose oxidases; vectors and host cells containing the nucleic acids and methods for producing the glucose oxidase; compositions comprising said glucose oxidase; methods for the preparation and production of such enzymes; and to methods for using such enzymes for food and feed processing, for the measurement of free glucose in clinical samples and bioreactors, and the development of miniature biofuel cells.

Abstract: The present invention is directed to nucleic acid sequences coding for a protein which, (1) under a respective promoter, is able to suppress or repress or delay flowering of a plant, and (2) includes the motive “NAPDIIDS” (SEQ ID NO: 10) or, in preferred cases, “VNAPDIIDS” SEQ ID NO: 67), with the exception of the nucleic acid of the gene StSP5G or a part thereof. Preferably, the nucleic acid sequence belongs phylogenetically to the FT-clade of the PEBP gene family, wherein the motive “(V)NAPDIIDS” (SEQ ID NO: 68) is in place of the “(V)YAPGW” motive_ (SEQ ID NO: 69) of the flowering promoting proteins AtFT and BvFT2. The invention is further directed to peptides or proteins, obtainable by expression of the nucleic acid of any of the preceding claims, vectors, comprising a nucleic acid sequence as defined above, and to plants, parts of plants, or seed of plants, the plants comprising such a nucleic acid sequence.